Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)
- Conditions
- Ewing Sarcoma Family of TumorsRhabdomyosarcomaCentral Nervous System TumorLeukemiaNeuroblastomaOsteosarcoma
- Interventions
- Other: Sampling on blood, bone marrow and cerebrospinal fluid
- Registration Number
- NCT03496402
- Lead Sponsor
- Institut Curie
- Brief Summary
Methodology:
Prospective, multicentric, open, non-randomised, non-therapeutic, interventional study
- Detailed Description
To identify and characterise:
* meaningful molecular genetic alterations,
* meaningful immunological features of high risk childhood, adolescents and young adult cancers, at diagnosis, during patient treatment and follow-up (time dimension).
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 600
-
Inclusion within 3 months after diagnosis
-
Availability of a cryopreserved tumour sample (primary and/or metastatic and/or lymph nodes) or peripheral blood or bone marrow samples (if invasion more than 30% of lymphoblasts) for leukaemias, obtained at the time of diagnosis during a routine procedure
-
Availability of a formalin-fixed paraffin-embedded (FFPE) tumour sample (primary and/or metastasis and/or lymph nodes), obtained at the time of diagnosis during a routine procedure (except for leukaemia patients)
-
Age: ≤ 25 years at diagnosis
-
Written patient informed consent, or parents or legal representative written informed consent and assent of the child and the adolescent
-
Compulsory affiliation to a social security scheme
Additional inclusion criteria for the study:
To avoid multiple sampling for children, adolescents and young adults with cancer, patients already included or to be included in a study with similar analyses and/or objectives might also be included in MICCHADO study and in this case, samples or data might be exchanged on a collaborative basis.
Cohort 1:
-
High risk neuroblastoma:
-
Any type of neuroblastoma with MYCN amplification, except INSS stage 1
-
Stage 4 neuroblastoma in children older than one year at diagnosis
-
-
High risk rhabdomyosarcoma:
- Foxo1 rearrangement any stage;
- and / or N1 ;
- and / or metastatic rhabdomyosarcoma
-
High risk Ewing sarcoma:
- Metastatic Ewing sarcoma family of tumours (ESFT)
- Localised inoperable Ewing sarcoma with primary tumours ≥ 200 ml
-
High risk osteosarcoma:
-
Metastatic osteosarcoma
-
Localised inoperable osteosarcoma
-
-
High risk leukaemia:
- Secondary acute myeloid leukaemia
- Biphenotypic acute leukaemia
Cohort 2:
• Extra cerebral or cerebral high risk tumours including:
- other metastatic sarcomas,
- other rare high risk cancers,
- high risk renal tumours with surgery after an initial chemotherapy
- rhabdoid brain tumours (AT/RT) and extra cerebral rhabdoid tumours
- high risk or metastatic cancers of unclear histological diagnosis • Lymphoblastic leukaemia with high MRD at Day 78 (time point 2) • Very high risk T-cells acute lymphoblastic leukaemia:
- MRD ≥ 10-2 at the end of the induction ;
- or MRD ≥ 10-3 at Day 78
Cohort 3:
Children, adolescents and young adults, with low/intermediate risk cancers belonging to the following types:
• Neuroblastoma:
- Localised, without MYCN amplification
-
Localised, INSS stage 1, with MYCN amplification
-
Stage 4s, in infants (younger than one year at diagnosis), without MYCN amplification
• Rhabdomyosarcoma:
-
Localised, without Foxo1 rearrangement
• ESFT:
-
All non-high risk localised ESFT • Osteosarcoma:
-
All non-high risk localised osteosarcoma
-
Main non-inclusion Criteria common to all study cohorts:
- Age: patients > 25 years old at diagnosis 2) Absence of patient or parents or legal representative written informed consent 3) Patient for whom follow-up by the investigating centre does not appear feasible
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description High risk Cohorts Sampling on blood, bone marrow and cerebrospinal fluid Cohort 1 : High risk Neuroblastoma, High risk Rhabdomyosarcoma, High risk Ewing Sarcoma Family Tumor, High risk Osteosarcoma, High risk Leukaemia (secondary acute myeloid leukaemia or biphenotypic acute leukaemia) Cohort 2 : Extracerebral and cerebral high risk tumor, High risk Leukaemia (leukaemia with high MRD) Sampling on blood, bone marrow and cerebrospinal fluid Low risk Cohort Sampling on blood, bone marrow and cerebrospinal fluid Cohort 3 : Intermediate or low risk tumors : Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family Tumor, Osteosarcoma Sampling on blood, bone marrow and cerebrospinal fluid
- Primary Outcome Measures
Name Time Method Number of patients with meaningful immunological features At the end of study (6 years) Identification and characterisation of the tumor microenvironment and the host's immunological profile, at diagnosis and during patient treatment
Number of patients with meaningful molecular genetic alterations At the end of study (6 years) Identification of molecular genetic alterations based on molecular characterisation of tumor at diagnosis, during patient treatment and follow-up (time dimension)
Number of patients with identification of new tumor-specific genetic characteristics during follow-up (clonal evolution) up to 6 years Comparison between genetic variations identified at diagnosis and those identified on circulating tumor DNA during treatment, FU and/or relapse
- Secondary Outcome Measures
Name Time Method Correlation between disease staging and immunological features up to 6 years To investigate the impact of the tumour microenvironment and host's immunological profile on the disease staging at diagnosis, by comparing patients with metastatic to patients with localised disease
Correlation between genetic variations and immune parameters up to 6 years To compare molecular and immunological findings at diagnosis and during treatment (data integration)
Correlation between disease recurrence and molecular and/or immunological biomarkers up to 6 years To characterise biomarkers, based on molecular analyses of tumour samples from diagnosis, for prognostic and predictive purposes.
To characterise the tumour microenvironment and the host's immunological profile, for prognostic and predictive purposes.
To identify potential prognostic and predictive biomarkers on samples collected during patient's treatment and follow-up, based on changes on circulating tumour DNA (ctDNA), detected by molecular biology techniques, and on immunological findings
Trial Locations
- Locations (30)
Hôpital d'Enfants Armand-Trousseau
🇫🇷Paris, France
Hôpital universitaire Robert-Debré (AP-HP)
🇫🇷Paris, France
Hôpital l'Archet 2
🇫🇷Nice, France
Chu D'Amiens Picardie
🇫🇷Amiens, France
CHU Angers
🇫🇷Angers, France
CHRU de Besançon - Hôpital Jean-Minjoz
🇫🇷Besançon, France
CHU de Bordeaux - Hôpital des enfants - Groupe Hospitalier Pellegrin
🇫🇷Bordeaux, France
CHRU de Brest
🇫🇷Brest, France
CHU CAEN
🇫🇷Caen, France
Centre Régional de Cancérologie et Thrapie Cellulaire Pdiatrique (CRCTCP)
🇫🇷Clermont-Ferrand, France
CHU Hôpital d'Enfants
🇫🇷Dijon, France
CHU GRENOBLE Alpes - Hôpital Couple-Enfant
🇫🇷Grenoble, France
Centre Oscar Lambret
🇫🇷Lille, France
CHU de Limoges - Hôpital Mère-Enfant
🇫🇷Limoges, France
Centre Léon Bérard
🇫🇷Lyon, France
Hospices Civils de Lyon
🇫🇷Lyon, France
Hôpital d'Enfants de la Timone (AP-HM)
🇫🇷Marseille, France
CHU Arnaud de Villeneuve
🇫🇷Montpellier, France
CHU Nantes - Hôpital Mère Enfant
🇫🇷Nantes, France
Institut Curie
🇫🇷Paris, France
CHU de Poitiers
🇫🇷Poitiers, France
CHU de Reims - Hôpital Américain
🇫🇷Reims, France
Chu Hopital Sud Rennes
🇫🇷Rennes, France
CHU de Rouen - Hôp. Charles NICOLLE
🇫🇷Rouen, France
CHU Saint-Etienne - Hôpital Nord
🇫🇷Saint-Étienne, France
Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
🇫🇷Strasbourg, France
CHU Hôpital des Enfants
🇫🇷Toulouse, France
CHU TOURS - Hôpital Clocheville
🇫🇷Tours, France
CHU Nancy - Hôpital d'Enfants
🇫🇷Vandoeuvre les Nancy, France
Gustave Roussy
🇫🇷Villejuif, France